20938-64-1

Basic information

• Product Name: Glycine, N-(3-aminobenzoyl)-
• Synonyms: N-(3-Amino-benzoyl)-glycin;3-Amino-hippursaeure;N-(3-amino-benzoyl)-glycine;3-Amino-benzaminoessigsaeure;Glycine, N-(3-aminobenzoyl)-
• CAS NO: 20938-64-1
• Molecular Formula: C9H10N2O3
• Molecular Weight: 194.19
• Mol File: 20938-64-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Glycine, N-(3-aminobenzoyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Glycine, N-(3-aminobenzoyl)-(20938-64-1)
• EPA Substance Registry System: Glycine, N-(3-aminobenzoyl)-(20938-64-1)

Safety Data

• Hazardous Substances Data: 20938-64-1(Hazardous Substances Data)

Upstream product

• 617-10-7 3-nitro-benzoyl glycine 
• 21563-72-4 3-Aminobenzoyl chloride 
• 56-40-6 glycine 
• 495-69-2 Hippuric Acid 
• 121-90-4 m-nitrobenzoic acid chloride 
• 99-05-8 meta-aminobenzoic acid 

Downstream Products

• 99-05-8 meta-aminobenzoic acid 
• 56-40-6 glycine 
• 1229653-27-3 C₂₀H₂₅N₃O₄ 
• 133604-61-2 (3-Benzoylamino-benzoylamino)-acetic acid 
• 1637-75-8 (3-hydroxybenzamido)acetic acid 
• 52386-94-4 2-(3-iodobenzamido)acetic acid 

Relevant articles and documents

Exploration of secondary and tertiary pharmacophores in unsymmetrical N,N′-diaryl urea inhibitors of soluble epoxide hydrolase

The impact of various secondary and tertiary pharmacophores on in vitro potency of soluble epoxide hydrolase (sEH) inhibitors based on the unsymmetrical urea scaffold 1 is discussed. N,N′-Diaryl urea inhibitors of soluble epoxide hydrolase exhibit subtle variations in inhibitory potency depending on the secondary pharmacophore but tolerate considerable structural variation in the second linker/tertiary pharmacophore fragment.

Synthesis and in Vitro Aldolase Reductase Inhibitory Activity of Compounds Containing an N-Acylglycine Moiety

A number of N-benzoylglycines (6), N-acetyl-N-phenylglycines (7), N-benzoyl-N-phenylglycines (8), and tricyclic N-acetic acids (9-12) were synthesized as analogues of the N-acylglycine-containing aldolase reductase inhibitors alrestatin and 2-oxoquinoline-1-acetic acid.Derivatives of 6, which represent ring-simplified analogues of alrestatin, are very weak inhibitors of aldolase reductase obtained from rat lens, producing 50percent inhibition only at concentrations exceeding 100 μM.Compounds of series 7 were designed as ring-opened analogues of the 2-oxoquinolines.While this derivatives are more potent than compounds of series 6 (IC 50s of 6-80 μM), they are less active than the corresponding 2-oxoquinolines.Analogues of series 8 were designed as hybrid structures of both alrestatin and the 2-oxoquinoline-1-acetic acids.These compounds are substantially more potent than compounds of series 6 and 7 and display inhibitory activities comparable to or greater than alrestatin or the 2-oxoquinolines (IC 50s of 0.1-10 μM).Of the rigid analogues of 8, the most potent derivative is benzoxindol (12) with an IC 50 of 0.67 μM, suggesting that fusion of the two aromatic rings of 8 in a coplanar conformation may optimize affinity for aldose reductase in this series.